Retrospective Analysis of Phase 4 Clinical Trial to Evaluate the Sustained Effect of Droxidopa in Symptomatic Neurogenic Orthostatic Hypotension

One of the biggest challenges patients with rare diseases face is the availability of safe and effective treatment options. Patients with symptomatic neurogenic orthostatic hypotension have a very limited number of pharmacological treatment options available, none of which are approved by the FDA for long term use. This study reviewed preliminary data from a single site in a nationwide clinical trial testing the long-term effectiveness of Droxidopa in patients with symptomatic neurogenic orthostatic hypotension. Long-term effectiveness was measured using two different patient reported surveys completed at various time points in the study. This data was analyzed using a linear regression as well as other descriptive statistics like mean, median, mode and range to assess the effectiveness of Droxidopa over time.